In 1999, a subject with ornithine transcarbamylase (OTC) deficiency died in a US in vivo gene therapy trial to assess the safety of an adenoviral vector carrying a functional copy of OTC(8). Here, OTC is linked to ornithine carbamoyltransferase deficiency.